START WITH YOUR QUESTION

Explore the evidence by outcome

Find what has been assessed, who or what was studied, and the limits of the finding.

This finder uses the same selected-source assessments as the peptide and stack guides. Evidence types describe the underlying source research, which may be indirect for the requested outcome. Filters select existing assessments; they do not recalculate grades or establish treatment recommendations. Topics without an outcome assessment remain in the peptide directory.

Clear all filters

32 assessments match these filters. Showing 12 on page 2 of 2.

Select two assessments below. This compares their scope, not treatment effectiveness.

BPC-157 · Peptide assessment

Reported symptom changes

Human research

Population / model
1,039 documented users;354 with response direction
Formulation / route
Study-specific; no cross-route equivalence assumed
Study design
Retrospective clinical-note study; preprint not peer reviewed

A September 2026 preprint identified 1,039 documented users; 279 of the 354 with a recorded response direction had reported improvement, while 685 lacked a recorded response direction.[1] It was not peer reviewed at this check, and missing outcomes, co-treatments and no control group prevent interpreting these counts as an effectiveness rate.[1] The much larger number of documented users improves the description of real-world use, but it does not resolve the missing outcomes or introduce the comparison group needed to estimate a treatment effect.[1]

Main limitation: Selection, missingness and confounding.[1]

Very lowRead the complete assessment

KLOW stack · Stack assessment

Safety of KPV-containing combinations

Context sources

Population / model
Human safety information is insufficient
Formulation / route
KPV-containing drug products
Study design
Regulatory safety assessment

FDA identifies a major human safety-information gap for KPV.[2]

Main limitation: A safety-information gap cannot establish that a combination is safe or quantify its risk.[2]

LowRead the complete assessment

Collagen peptides · Peptide assessment

Short-term skin elasticity

Human research

Population / model
69 women aged 35–55, eight weeks
Formulation / route
Oral collagen hydrolysate
Study design
Small randomized double-blind placebo-controlled trial

A randomized trial reported improved skin elasticity with a specific oral collagen preparation.[3] In one double-blind trial, 69 women aged 35–55 were assigned collagen hydrolysate or placebo for eight weeks; elasticity improved relative to placebo, while moisture-related findings were not statistically significant.[3] This is a short-term signal in a narrow population rather than proof of broad skin rejuvenation.[3]

Main limitation: Short duration, narrow population, and product-specific findings.[3]

LowRead the complete assessment

GLOW stack · Stack assessment

Skin improvement from the GLOW blend

Human research

Population / model
13 completers after CO2 laser resurfacing
Formulation / route
Topical GHK-Cu, not the injected three-peptide blend
Study design
Indirect topical human trial

This study tests a skin regimen rather than GLOW.[4]

Main limitation: Route and intervention differ from the stack.[4]

LowRead the complete assessment

Ipamorelin · Peptide assessment

Sleep quality or training recovery

Human research

Population / model
Healthy volunteers and postoperative bowel-resection patients
Formulation / route
Intravenous studies; subcutaneous combination claims not established
Study design
Human pharmacology and unrelated clinical-indication studies

The human studies reviewed here do not establish that ipamorelin improves sleep quality or training recovery, either alone or combined with CJC-1295.[5][6] Early human work examined its pharmacokinetics and growth-hormone response, while a later randomized trial studied intravenous ipamorelin after bowel surgery.[5][6] Neither setting directly tests the sleep or recovery claims made for subcutaneous combinations.[5][6]

Main limitation: No matched clinical-outcome trial identified for these claims.[5][6]

No direct human evidenceRead the complete assessment

CJC-1295 + ipamorelin · Stack assessment

Sleep, muscle, or recovery benefit from the pair

Human research

Population / model
Healthy adult volunteers
Formulation / route
Long-acting CJC-1295 or intravenous ipamorelin, studied separately
Study design
Indirect single-agent human studies

Separate hormone-response studies cannot establish the combination’s clinical benefit.[5][7]

Main limitation: The intervention and endpoints differ from the stack claims.[5][7]

LowRead the complete assessment

BPC-157 · Peptide assessment

Structural tendon or ligament healing

Human and preclinical research

Population / model
Knee-pain patients and surgically injured rats
Formulation / route
Study-specific; no cross-route equivalence assumed
Study design
Human case series indirect for structural repair; exploratory rat repair experiment

The knee-pain case series measured subjective symptoms, without objective confirmation of tendon or ligament repair.[8] In a 2026 rat Achilles-repair experiment, BPC-157 alone did not significantly improve maximum load to failure versus control.[9] That experiment used four tendons per group for each endpoint, so its nonsignificant result does not establish that no effect exists.[9]

Main limitation: Symptoms and preclinical endpoints do not establish human structural repair.[8][9]

No direct human evidenceRead the complete assessment

GHK-Cu · Peptide assessment

Topical skin-quality improvement

Human research

Population / model
13 completers after CO2 laser resurfacing
Formulation / route
Topical copper-tripeptide skin-care regimen
Study design
Small randomized post-procedure trial

The selected topical trial provides limited, procedure-specific evidence for GHK-Cu.[4] In a randomized study after carbon dioxide laser resurfacing, 13 patients completed follow-up.[4] Participants using the copper-peptide regimen reported greater improvement in overall skin quality, but objective assessments found no significant between-group improvement in wrinkles, overall skin quality, or resolution of redness.[4]

Main limitation: Small sample, mixed endpoints, procedure-specific context.[4]

LowRead the complete assessment

Tirzepatide · Peptide assessment

Weight maintenance after continuation versus withdrawal

Human research

Population / model
670 participants randomized after 36 weeks of treatment
Formulation / route
Continuation or withdrawal of subcutaneous tirzepatide
Study design
Randomized withdrawal trial after open-label lead-in

Many participants regained weight after tirzepatide withdrawal in SURMOUNT-4.[10] After a 36-week initial treatment period, 670 participants were randomized either to continue tirzepatide or switch to placebo.[10] During the next 52 weeks, the placebo group gained an average 14.0% relative to its weight at randomization, while those continuing tirzepatide lost a further 5.5%.[10]

Main limitation: Enriched for participants able to reach randomization.[10]

HighRead the complete assessment

Semaglutide · Peptide assessment

Weight reduction over 68 weeks

Human research

Population / model
1,961 adults with overweight or obesity without diabetes
Formulation / route
Studied subcutaneous pharmaceutical formulation
Study design
Large double-blind randomized placebo-controlled trial

In STEP 1, 1,961 adults with overweight or obesity without diabetes were randomized to subcutaneous semaglutide or placebo, both alongside lifestyle intervention.[11] At 68 weeks, average weight change was −14.9% with semaglutide and −2.4% with placebo.[11] This provides strong evidence of average weight reduction in the studied population, but it is not a forecast for an individual or evidence for an unverified research-use product.[11]

Main limitation: Average trial response does not predict an individual's result.[11]

HighRead the complete assessment

Tirzepatide · Peptide assessment

Weight reduction over 72 weeks

Human research

Population / model
2,539 adults with overweight or obesity without diabetes
Formulation / route
Studied subcutaneous pharmaceutical formulation
Study design
Large double-blind randomized placebo-controlled trial

SURMOUNT-1 randomized 2,539 adults with obesity, or overweight with a weight-related complication, without diabetes.[12] Across the three studied tirzepatide groups, average weight reduction at 72 weeks ranged from 15.0% to 20.9%, compared with 3.1% with placebo.[12] The size and randomized design support a strong conclusion about average weight reduction under the trial conditions.[12]

Main limitation: Effects depend on the studied population and treatment conditions.[12]

HighRead the complete assessment

Semaglutide · Peptide assessment

Weight regain after withdrawal

Human research

Population / model
327 participants in the STEP 1 extension
Formulation / route
Withdrawal after studied subcutaneous semaglutide
Study design
Observational extension of a randomized trial

Weight regain was substantial after treatment ended in the STEP 1 extension.[13] In the extension group, participants previously assigned semaglutide regained an average 11.6 percentage points of body weight during the following year, approximately two-thirds of their earlier loss, leaving an average net reduction of 5.6% from the original baseline.[13] This was follow-up of a subset of the original trial, and structured lifestyle intervention also stopped, so it cannot isolate every contributor to regain.[13]

Main limitation: Selected follow-up subset; drug and lifestyle intervention both stopped.[13]

ModerateRead the complete assessment

How certainty is assessed · Study reviews and review coverage